Company Filing History:
Years Active: 1996
Title: Bruce Altrock: Innovator in Monoclonal Antibody Development
Introduction
Bruce Altrock is a notable inventor based in Newbury Park, California. He has made significant contributions to the field of immunology through his innovative work on hybridoma cell lines and monoclonal antibodies. His research has implications for the detection and isolation of critical human proteins.
Latest Patents
Bruce Altrock holds a patent for "Hybridoma cell lines and their monoclonal antibodies to human." This patent involves murine-derived hybridoma tumor cell lines and the monoclonal anti-human pluripotent Granulocyte Colony Stimulating Factor antibody substances produced by these cell lines. The use of these monoclonal antibody substances is crucial for immunological procedures aimed at isolating human pluripotent Granulocyte Colony Stimulating Factor and for quantitatively detecting this factor in fluid samples. He has 1 patent to his name.
Career Highlights
Throughout his career, Bruce has been associated with Kirin-Amgen, Inc., where he has contributed to various research projects. His work has been instrumental in advancing the understanding of granulocyte colony-stimulating factors and their applications in medical science.
Collaborations
Bruce Altrock has collaborated with David Chang, a fellow researcher, to further explore the potential of monoclonal antibodies in clinical applications. Their partnership has led to advancements in the field and has fostered innovation in immunological research.
Conclusion
Bruce Altrock's contributions to the field of immunology through his patent on hybridoma cell lines and monoclonal antibodies highlight his role as an innovator. His work continues to impact the scientific community and improve medical practices.